Cargando…

P917: HOW COMORBID ARE OUR MYELOMA PATIENTS AND HOW MANY MAKE IT TO THE SECOND-LINE TREATMENT: REAL-WORLD DATA OF 251 MYELOMA PATIENTS TREATED IN THE HEMATOLOGICAL NETWORK OF THE OEGK

Detalles Bibliográficos
Autores principales:	Keil, F., Attalla, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431321/ http://dx.doi.org/10.1097/01.HS9.0000846536.28395.e7

Ejemplares similares

P917: SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: UPDATED RESULTS OF BOSTON TRIAL BY PRIOR THERAPIES
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Nonsecretory multiple myeloma, how to make a diagnosis?
por: Wiwanitkit, Viroj
Publicado: (2010)

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
por: de Arriba de la Fuente, Felipe, et al.
Publicado: (2022)

Immunotherapy in myeloma: Why, when and how?
por: van de Donk, Niels W.C.J.
Publicado: (2018)

Management of patients with multiple myeloma in the era of COVID-19 pandemic: how hospital at home changes our medical practice
por: Fouquet, G., et al.
Publicado: (2021)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

How We Approach Smoldering Multiple Myeloma
por: Raje, Noopur, et al.
Publicado: (2020)

How I approach smoldering multiple myeloma
por: Vaxman, Iuliana, et al.
Publicado: (2022)

How many kinases are druggable? A review of our current understanding
por: Anderson, Brian, et al.
Publicado: (2023)

Immunotherapy in myeloma: how far have we come?
por: Franssen, Laurens E., et al.
Publicado: (2019)

How I treat relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2020)

Game of Bones: How Myeloma Manipulates Its Microenvironment
por: Moser-Katz, Tyler, et al.
Publicado: (2021)

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
por: Jones, J R, et al.
Publicado: (2016)

917. Infectious Diseases Consult Improves Management of Candidemia
por: Stornelli, Nick, et al.
Publicado: (2022)

Validation of the Revised Myeloma Comorbidity Index and other comorbidity scores in a multicenter German study group multiple myeloma trial
por: Dold, Sandra Maria, et al.
Publicado: (2020)

How I manage frontline transplant-ineligible multiple myeloma
por: Derudas, Daniele, et al.
Publicado: (2020)

How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma
por: Morris, Treen Carson Michael, et al.
Publicado: (2021)

Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma
por: Johnson, David C., et al.
Publicado: (2016)

Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005–2016
por: Toppila, Iiro, et al.
Publicado: (2022)

Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients
por: Avivi, Irit, et al.
Publicado: (2023)

How many will it take?
por: Mercier, Eric, et al.
Publicado: (2008)

How Many Psychiatrists?
por: Smith, Andrew
Publicado: (1968)

How many hospitalisations?
por: Wilson, Clare
Publicado: (2021)

PB1993: MULTIPLE MYELOMA BRAZILIAN REGISTER- HOW ABOUT THE TRANSPLANT ELIGIBLE PATIENTS?
por: Crusoe, E., et al.
Publicado: (2022)

How Many People Need Palliative Care and How Many Miss Out?
por: Davis, Esther, et al.
Publicado: (2020)

Sample size: how many patients are necessary?
por: Fayers, P. M., et al.
Publicado: (1995)

If so many are “few,” how few are “many”?
por: Heim, Stefan, et al.
Publicado: (2015)

Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone
por: Alkharabsheh, Omar, et al.
Publicado: (2023)

Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies
por: Ravi, Praful, et al.
Publicado: (2018)

Controlling how many cells make a fly
por: Moore, Pete
Publicado: (2003)

How should multiple myeloma research change in a patient-oriented world? Findings and lessons from the pan-Canadian myeloma priority setting partnership
por: Bridges, Sarah, et al.
Publicado: (2023)

Multicentre evaluation of the Boehringer Mannheim/Hitachi 917 analysis system
por: van Suijlen, Jeroen D. E., et al.
Publicado: (2000)

917 Nosocomial Respiratory Viral Infections in Two Children's Hospitals
por: Shah, Rita, et al.
Publicado: (2014)

POS-917 COVID-19 CAUSED CHRONIC KIDNEY DISEASE
por: Viazelda, A.T., et al.
Publicado: (2022)

How Our School Makes Doctors
por: Kinslow, Josephus Eleanorus
Publicado: (1880)

A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients
por: Engelhardt, Monika, et al.
Publicado: (2017)

Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?
por: Nguyen-Pham, Thanh-Nhan, et al.
Publicado: (2012)

Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?
por: Cooke, Rachel E., et al.
Publicado: (2019)

How I manage frontline transplant-eligible multiple myeloma in Italy
por: Montefusco, Vittorio, et al.
Publicado: (2020)

How Can Imaging Help the Radiation Oncologist in Multiple Myeloma Treatment
por: Belgioia, Liliana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_44v34cr5vfg0fg49158cnqe0oi